SBFM
Price
$2.76Alerts
Change
-$0.08 (-2.82%)
Updated
Nov 13, 12:49 PM (EDT)
Capitalization
10.51M
110 days until earnings call
Intraday BUY SELL Signals
TXMD
Price
$1.89Alerts
Change
+$0.07 (+3.85%)
Updated
Nov 13, 02:07 PM (EDT)
Capitalization
20.14M
Intraday BUY SELL Signals
Interact to see
Advertisement

SBFM vs TXMD

SBFM vs TXMD Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
SBFM vs. TXMD commentary
Nov 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SBFM is a Hold and TXMD is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for SBFM with price predictions
Nov 12, 2026

SBFM's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for SBFM turned positive on October 23, 2026. Looking at past instances where SBFM's MACD turned positive, the stock continued to rise in 35 of 43 cases over the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SBFM's RSI Indicator exited the oversold zone, 40 of 52 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 73 cases where SBFM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.

Following a +5.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where SBFM advanced for three days, in 117 of 166 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SBFM as a result. In 85 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBFM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for SBFM entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.382) is normal, around the industry mean (6.379). P/E Ratio (-0.296) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.070) is also within normal values, averaging (183.387).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. SBFM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SBFM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
a Summary for TXMD with price predictions
Nov 12, 2026

TXMD's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for TXMD turned positive on November 11, 2026. Looking at past instances where TXMD's MACD turned positive, the stock continued to rise in 40 of 52 cases over the following month. The odds of a continued upward trend are 77%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TXMD's RSI Oscillator exited the oversold zone, 28 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

Following a +9.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXMD advanced for three days, in 145 of 207 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

TXMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TXMD as a result. In 95 of 113 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TXMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for TXMD entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.742) is normal, around the industry mean (6.379). P/E Ratio (-87.000) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (7.740) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. TXMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

FUNDAMENTALS RATINGS
SBFM vs TXMD: Fundamental Ratings
SBFM
TXMD
OUTLOOK RATING
1..100
145
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
5
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9691
PRICE GROWTH RATING
1..100
9760
P/E GROWTH RATING
1..100
9898
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TXMD's Valuation (5) in the Pharmaceuticals Generic industry is in the same range as SBFM (30) in the null industry. This means that TXMD’s stock grew similarly to SBFM’s over the last 12 months.

TXMD's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as SBFM (100) in the null industry. This means that TXMD’s stock grew similarly to SBFM’s over the last 12 months.

TXMD's SMR Rating (91) in the Pharmaceuticals Generic industry is in the same range as SBFM (96) in the null industry. This means that TXMD’s stock grew similarly to SBFM’s over the last 12 months.

TXMD's Price Growth Rating (60) in the Pharmaceuticals Generic industry is somewhat better than the same rating for SBFM (97) in the null industry. This means that TXMD’s stock grew somewhat faster than SBFM’s over the last 12 months.

TXMD's P/E Growth Rating (98) in the Pharmaceuticals Generic industry is in the same range as SBFM (98) in the null industry. This means that TXMD’s stock grew similarly to SBFM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SBFMTXMD
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
70%
Bullish Trend 3 days ago
70%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 22 days ago
87%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
60%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
COMPARISON
Comparison
Nov 13, 2026
Stock price -- (SBFM: $2.84 vs. TXMD: $1.82)
Brand notoriety: SBFM and TXMD are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: SBFM: 10% vs. TXMD: 23%
Market capitalization -- SBFM: $10.51M vs. TXMD: $20.14M
SBFM [@Pharmaceuticals: Generic] is valued at $10.51M. TXMD’s [@Pharmaceuticals: Generic] market capitalization is $20.14M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SBFM’s FA Score shows that 1 FA rating(s) are green while TXMD’s FA Score has 1 green FA rating(s).

  • SBFM’s FA Score: 1 green, 4 red.
  • TXMD’s FA Score: 1 green, 4 red.
According to our system of comparison, TXMD is a better buy in the long-term than SBFM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SBFM’s TA Score shows that 4 TA indicator(s) are bullish while TXMD’s TA Score has 4 bullish TA indicator(s).

  • SBFM’s TA Score: 4 bullish, 3 bearish.
  • TXMD’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SBFM is a better buy in the short-term than TXMD.

Price Growth

SBFM (@Pharmaceuticals: Generic) experienced а +1.79% price change this week, while TXMD (@Pharmaceuticals: Generic) price change was +6.43% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.98%. For the same industry, the average monthly price growth was -6.01%, and the average quarterly price growth was +6.11%.

Reported Earning Dates

SBFM is expected to report earnings on Mar 03, 2027.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.98% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
Interact to see
Advertisement

SBFM and

Correlation & Price change

A.I.dvisor tells us that SBFM and SXTC have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SBFM and SXTC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBFM
1D Price
Change %
SBFM100%
+3.27%
SXTC - SBFM
31%
Poorly correlated
-3.53%
OGI - SBFM
28%
Poorly correlated
-2.31%
CGC - SBFM
24%
Poorly correlated
-5.16%
TLRY - SBFM
24%
Poorly correlated
-4.60%
ELAN - SBFM
23%
Poorly correlated
+0.08%
More

TXMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, TXMD has been loosely correlated with LIEN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if TXMD jumps, then LIEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TXMD
1D Price
Change %
TXMD100%
-1.62%
LIEN - TXMD
36%
Loosely correlated
-1.31%
IMCC - TXMD
24%
Poorly correlated
-3.83%
ACB - TXMD
23%
Poorly correlated
-1.19%
BCRX - TXMD
22%
Poorly correlated
+0.39%
SBFM - TXMD
22%
Poorly correlated
+3.27%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GIFT0.560.03
+5.62%
Giftify Inc
HBNB4.440.02
+0.45%
Hotel101 Global Holdings Corp.
MAGH6.76N/A
N/A
Magnitude International Ltd.
MPWR1447.40-31.29
-2.12%
Monolithic Power Systems
HLNE93.88-2.90
-3.00%
Hamilton Lane